SKD Pharmaceuticals® has laid the groundwork for its expansion into B2B private label manufacturing services alongside its continued focus on the pharmaceutical market. As part of its strategic growth plans, SKD Pharmaceuticals® aims to acquire a UK-based manufacturing site and achieve MHRA accreditation, enabling it to produce high-quality pharmaceutical and skincare products.
Under these plans, SKD Pharmaceuticals® will introduce a private label manufacturing service tailored for B2B clients. The manufacturing focus will span:
- Pharmaceutical-Grade OTC Products: MHRA-approved skincare preparations.
- Spa-Grade and Salon-Grade Skincare Products: Designed for premium markets, including salons, spas, and retail outlets.
Currently, SKD Pharmaceuticals® offers vitamins and supplements manufactured in the UK to GMP standards and ISO:9001 certifications. However, these products are not part of the private label offering.
A Vision for Innovation and Accessibility
In a statement, SKD Pharmaceuticals® shared:
“An MHRA-accredited facility will enable us to enter the OTC pharmaceutical market, allowing us to research and manufacture revolutionary skincare treatments that make a meaningful impact on people’s lives. Upon MHRA approval, we also plan to develop and produce oral generic medicines, primarily tablets, entirely in the UK to address various health conditions.”
The company emphasised its commitment to supporting businesses of all sizes through its private label services:
“Our spa-grade and cosmetic-grade products will be available under a comprehensive private label/white label scheme. From concept to manufacturing, testing, packaging, and labelling, we offer an end-to-end service that ensures a finished product ready for market. We cater to large-scale retailers, pharmacies, salons, spas, and hotels on an international level.”
SKD Pharmaceuticals® also highlighted its dedication to small businesses and startups, offering some of the lowest minimum order quantities in the industry:
“We recognise the challenges faced by new startups and niche brands, particularly with high-volume order pressures. To address this, we will offer exceptionally low minimum quantities, making it easier for small businesses to create their own dream brand. This is a great starting point for entrepreneurs to build a successful, high-quality brand.”
Next Steps
Further details will be shared once the manufacturing facility is finalised, and all automated pharmaceutical equipment has been installed and tested.
For further information and to stay updated please visit www.skdpharmaceuticals.com